These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 30991401

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.
    Chiloff DM, de Almeida DC, Dalboni MA, Canziani ME, George SK, Morsi AM, El-Akabawy N, Porada CD, Durao MS, Zarjou A, Almeida-Porada G, Goes MA.
    Am J Physiol Renal Physiol; 2020 Apr 01; 318(4):F861-F869. PubMed ID: 32003597
    [Abstract] [Full Text] [Related]

  • 5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.
    Ther Apher Dial; 2010 Jun 01; 14(3):240-75. PubMed ID: 20609178
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New Treatment Approaches for the Anemia of CKD.
    Bonomini M, Del Vecchio L, Sirolli V, Locatelli F.
    Am J Kidney Dis; 2016 Jan 01; 67(1):133-42. PubMed ID: 26372086
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
    Ingrasciotta Y, Lacava V, Marcianò I, Giorgianni F, Tripepi G, D' Arrigo G, Chinellato A, Ugo Tari D, Santoro D, Trifirò G.
    BMC Nephrol; 2019 Sep 14; 20(1):359. PubMed ID: 31521117
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
    Kuwahara M, Arai Y, Takehara E, Sasaki Y, Yoshimine T, Kusaka K, Shikuma S, Akita W, Uchida S.
    Clin Exp Nephrol; 2016 Aug 14; 20(4):585-594. PubMed ID: 26511877
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Investigational therapies for renal disease-induced anemia.
    Schmid H, Jelkmann W.
    Expert Opin Investig Drugs; 2016 Aug 14; 25(8):901-16. PubMed ID: 27122198
    [Abstract] [Full Text] [Related]

  • 14. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
    Beach LB, Wild M, Ramachandran G, Ikizler HO, Cavanaugh KL.
    BMC Nephrol; 2016 Jul 18; 17(1):86. PubMed ID: 27430294
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.